Company news

Adaptive Biotechnologies Corporation news in 2023

Adaptive Biotechnologies Corporation's news releases, calls and decks from 2023, newest first.

View company

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 26, 2023

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

December 8, 2023

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

December 4, 2023

Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline

November 6, 2023

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023

November 1, 2023

Adaptive Announces Launch of Epic Integration for clonoSEQ®

September 12, 2023

Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 29, 2023

Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results

August 1, 2023

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023

July 9, 2023

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

June 1, 2023

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

May 23, 2023

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

May 11, 2023

Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

May 8, 2023

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

May 2, 2023

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

April 24, 2023

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

April 11, 2023

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

April 5, 2023

Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

February 26, 2023

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results

February 13, 2023

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023

January 22, 2023

Calls in 2023

Decks in 2023